C6orf89: A Potential Drug Target Or Biomarker (G221477)

Target Name: C6orf89

NCBI ID: G221477

C6orf89

C6orf89: A Potential Drug Target Or Biomarker

C6orf89, also known as Bombesin receptor-activated protein (BRAP), is a protein that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique function and structure have made it an attractive target for researchers to study and develop new treatments.

C6orf89 is a protein that is expressed in many different tissues throughout the body, including the brain, spinal cord, heart, and blood vessels. It is made up of 21 kilodalton (kDa) of amino acids and has a calculated molecular mass of 22.9 kDa. One of the most interesting features of C6orf89 is its unique structure. It has a split cytoplasmic tail, which is not typical for a protein of its size. This split tail is composed of 12 amino acids and is involved in the protein's stability and localization to the plasma membrane.

C6orf89 is also known for its ability to interact with certain proteins, including the bombesin receptor. The bombesin receptor is a protein that is expressed in many different tissues throughout the body and is involved in the regulation of neurotransmitter signaling. When a neurotransmitter binds to the bombesin receptor, it triggers a signaling cascade that can have a variety of effects on the cell, including modulating the expression of other proteins and influencing the structure and function of the cell.

The combination of C6orf89's unique structure and its ability to interact with the bombesin receptor makes it an attractive target for researchers to study and develop new treatments. One of the main goals of research into C6orf89 is to understand its role in the regulation of neurotransmitter signaling and to identify its potential interactions with other proteins. This information can be used to develop new drugs or biomarkers that can be used to diagnose and treat a variety of neurological and psychiatric disorders.

In addition to its potential as a drug target, C6orf89 has also been identified as a potential biomarker for a variety of diseases. The split cytoplasmic tail of C6orf89 makes it difficult to study in great detail, but researchers have been able to use techniques such as mass spectrometry to study its composition and to determine that it is expressed in a variety of tissues throughout the body. This suggests that C6orf89 could be used as a biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another promising aspect of C6orf89's potential as a drug target or biomarker is its expression in certain diseases. For example, studies have shown that C6orf89 is expressed in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder that is characterized by the progressive loss of brain cells. This suggests that C6orf89 may be involved in the development and progression of this disease. Similarly, C6orf89 has also been shown to be expressed in the brains of individuals with Parkinson's disease, another neurodegenerative disorder.

In addition to its potential as a drug target or biomarker, C6orf89 is also of interest to researchers because of its unique structure and function. The split cytoplasmic tail of C6orf89 is thought to be involved in its localization to the plasma membrane, where it can interact with the bombesin receptor. This interaction suggests that C6orf89 may be involved in the regulation of the movement and behavior of cells, as well as the regulation of neurotransmitter signaling.

Overall, C6orf89 is a protein that has a unique structure and function that makes it an attractive target for

Protein Name: Chromosome 6 Open Reading Frame 89

Functions: Exhibits histone deacetylase (HDAC) enhancer properties (PubMed:23460338). May play a role in cell cycle progression and wound repair of bronchial epithelial cells (PubMed:21857995)

The "C6orf89 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C6orf89 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets